JP2008514718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514718A5 JP2008514718A5 JP2007534730A JP2007534730A JP2008514718A5 JP 2008514718 A5 JP2008514718 A5 JP 2008514718A5 JP 2007534730 A JP2007534730 A JP 2007534730A JP 2007534730 A JP2007534730 A JP 2007534730A JP 2008514718 A5 JP2008514718 A5 JP 2008514718A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- composition
- aryl
- coor
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 229930182558 Sterol Natural products 0.000 claims 22
- 150000003432 sterols Chemical class 0.000 claims 22
- 235000003702 sterols Nutrition 0.000 claims 22
- 150000002148 esters Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 19
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 17
- 229960003015 rimonabant Drugs 0.000 claims 17
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 16
- 208000008589 Obesity Diseases 0.000 claims 16
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 16
- 206010012601 diabetes mellitus Diseases 0.000 claims 16
- 235000020824 obesity Nutrition 0.000 claims 16
- 210000002381 plasma Anatomy 0.000 claims 16
- 208000019553 vascular disease Diseases 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 15
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 claims 15
- 125000001424 substituent group Chemical group 0.000 claims 12
- 238000010521 absorption reaction Methods 0.000 claims 9
- 229960000815 ezetimibe Drugs 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 6
- -1 azetidinone compound Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*N(C(*)C1P)C1=O Chemical compound C*N(C(*)C1P)C1=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61416704P | 2004-09-29 | 2004-09-29 | |
| PCT/US2005/034812 WO2006039334A1 (en) | 2004-09-29 | 2005-09-27 | Combinations of substituted azetidonones and cb1 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008514718A JP2008514718A (ja) | 2008-05-08 |
| JP2008514718A5 true JP2008514718A5 (OSRAM) | 2008-11-06 |
Family
ID=35539341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007534730A Pending JP2008514718A (ja) | 2004-09-29 | 2005-09-27 | 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060069080A1 (OSRAM) |
| EP (1) | EP1807070A1 (OSRAM) |
| JP (1) | JP2008514718A (OSRAM) |
| CA (1) | CA2581596A1 (OSRAM) |
| MX (1) | MX2007003732A (OSRAM) |
| WO (1) | WO2006039334A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| AU2003291719A1 (en) * | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| ATE485267T1 (de) * | 2003-12-23 | 2010-11-15 | Astrazeneca Ab | Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
| AR057072A1 (es) * | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
| SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| FR2902008A1 (fr) * | 2006-06-07 | 2007-12-14 | Sanofi Aventis Sa | Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate |
| AU2007338625A1 (en) * | 2006-12-21 | 2008-07-03 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor |
| FR2919863A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| FR2919864A1 (fr) * | 2007-08-06 | 2009-02-13 | Sanofi Aventis Sa | Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
| EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| WO2013063526A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| EA030839B1 (ru) | 2011-10-28 | 2018-10-31 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей |
| JP2016514684A (ja) | 2013-03-15 | 2016-05-23 | ルメナ ファーマシューティカルズ エルエルシー | 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤 |
| CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
| FR3041641B1 (fr) * | 2015-09-25 | 2017-10-20 | Univ Nantes | 1,4-di-(4-methylthiophenyl)-3-phtaloylazetidine-2-one et ses derives |
| AU2020221834B2 (en) | 2019-02-12 | 2025-10-23 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4820850A (en) * | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
| US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
| US4983597A (en) * | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
| US5688785A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| DE69222532T2 (de) * | 1991-07-23 | 1998-02-26 | Schering Corp | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
| US5561227A (en) * | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
| US5688787A (en) * | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
| FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5656624A (en) * | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5668990A (en) * | 1995-03-30 | 1997-09-16 | Pitney Bowes Inc. | Apparatus and method for generating 100% United States Postal Service bar coded lists |
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| EA010183B1 (ru) * | 1997-05-14 | 2008-06-30 | Атеродженикс, Инк. | Сложный моноэфир янтарной кислоты и пробукола для лечения сердечно-сосудистых и воспалительных заболеваний |
| HN1998000027A (es) * | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| US6479479B2 (en) * | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| US6566356B2 (en) * | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| ES2272449T3 (es) * | 2000-03-23 | 2007-05-01 | Solvay Pharmaceuticals B.V. | Derivados de 4,5-dihidro-1h-pirazol con actividad antagosnista de cb-1. |
| DE10042447A1 (de) * | 2000-08-29 | 2002-03-28 | Aventis Pharma Gmbh | Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| EP1347987B1 (en) * | 2000-12-20 | 2004-10-13 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| HUP0401073A2 (hu) * | 2000-12-21 | 2004-09-28 | Aventis Pharma Deutschland Gmbh. | Difenilazetidinon-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| ES2277890T3 (es) * | 2000-12-21 | 2007-08-01 | Sanofi-Aventis Deutschland Gmbh | Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos. |
| IL156552A0 (en) * | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
| RS50386B (sr) * | 2001-03-28 | 2009-12-31 | Schering Corporation, | Enantioselektivna sinteza intermedijarnih jedinjenja azetidinona |
| US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| PL374860A1 (en) * | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| PL375230A1 (en) * | 2002-07-09 | 2005-11-28 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| PT1697371E (pt) * | 2003-12-19 | 2007-08-03 | Bristol Myers Squibb Co | Heterocíclos azabicíclicos como moduladores do receptor de canabinóides |
-
2005
- 2005-09-27 WO PCT/US2005/034812 patent/WO2006039334A1/en not_active Ceased
- 2005-09-27 MX MX2007003732A patent/MX2007003732A/es unknown
- 2005-09-27 JP JP2007534730A patent/JP2008514718A/ja active Pending
- 2005-09-27 EP EP05801849A patent/EP1807070A1/en not_active Withdrawn
- 2005-09-27 CA CA002581596A patent/CA2581596A1/en not_active Abandoned
- 2005-09-27 US US11/236,225 patent/US20060069080A1/en not_active Abandoned